United Therapeutics Corporation (UTHR)
| Market Cap | 7.33B |
| Revenue (ttm) | 1.41B |
| Net Income (ttm) | 468.60M |
| Shares Out | 44.40M |
| EPS (ttm) | 10.59 |
| PE Ratio | 15.57 |
| Forward PE | 13.32 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $164.85 |
| Previous Close | $169.35 |
| Change ($) | -4.50 |
| Change (%) | -2.66% |
| Day's Open | 170.09 |
| Day's Range | 163.40 - 170.74 |
| Day's Volume | 225,618 |
| 52-Week Range | 79.39 - 172.82 |
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 13, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that results from the INCREASE clinical study ...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 4, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairman and Chief ...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Dec. 28, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today an agreement to acquire a Rare Pediatric Disea...
After a 63% rise since the March 23 levels of this year, at the current price of around $137 per share we believe United Therapeutics stock (NASDAQ: UTHR), a biotechnology company, has reached...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Dec. 9, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that the United States Food and Drug Administra...
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Offic...
United Therapeutics Corporation (UTHR) CEO Martine Rothblatt on Q3 2020 Results - Earnings Call Transcript
United Therapeutics' (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso offset lower sales of Remodulin and Adcirca.
United Therapeutics (UTHR) delivered earnings and revenue surprises of 59.34% and 5.01%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for th...
Shares of United Therapeutics (NASDAQ:UTHR) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share increased 1.31% over the past year to $3.88, which b...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended Se...
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend mi...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 22, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced new clinical data on Tyvaso® (treprostinil) In...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2020 fin...
Earnings season is upon us and investors are pining for information about which stocks and sectors will do well.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced it will present clinical trial data on Tyvaso®...
REHOVOT, Israel and SILVER SPRING, Maryland, Sept. 21, 2020 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) and United Therapeutics Corporation (NASDAQ: UTHR) today announced an expan...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
United Therapeutics' (UTHR) INCREASE study evaluated Tyvaso in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
It's not uncommon for stocks that have significantly outperformed for several months to take a breather.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.
United Therapeutics' (UTHR) second-quarter sales beat estimates. Higher sales of Orenitram and Tyvaso offset lower sales of Remodulin and Adcirca.
United Therapeutics Corporation (UTHR) CEO Martine Rothblatt on Q2 2020 Results - Earnings Call Transcript
United Therapeutics (UTHR) delivered earnings and revenue surprises of 0.00% and 6.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of United Therapeutics (NASDAQ:UTHR) were unchanged after the company reported Q2 results.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.
There’s a select group of pharmaceutical stocks that stand to win without even looking for a Covid-19 cure. The post The 7 Best Pharmaceutical Stocks That Go Beyond the Covid-19 Chase appeare...
As the first half of 2020 comes to a close, investors are cautiously looking toward the remainder of the year as uncertainty surrounding the full impact the coronavirus will have on the econom...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 17, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that key data from the INCREASE study of Tyvas...
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 5, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has filed a lawsuit in the U.S. Distric...
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 26, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Office...
Amid the COVID-19 pandemic, the investing pros say that it’s still possible to unmask names poised to take off on an upward trajectory.
Does United Therapeutics (UTHR) have what it takes to be a top stock pick for momentum investors? Let's find out.
United Therapeutics (UTHR) beats estimates for both earnings and sales in first quarter. It expects a reduction in new patient starts in the future quarters.
United Therapeutics' (UTHR) CEO Martine Rothblatt on Q1 2020 Results - Earnings Call Transcript
United Therapeutics (UTHR) delivered earnings and revenue surprises of 28.40% and 2.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the st...
In the latest trading session, United Therapeutics (UTHR) closed at $93.90, marking a -0.98% move from the previous day.
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
Is (UTHR) Outperforming Other Medical Stocks This Year?
United Therapeutics: Potential Promising Despite Falling Sales
About UTHR
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and internationally. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to... [Read more...]
| Industry Biotechnology | IPO Date Jun 17, 1999 |
| CEO Martine Rothblatt | Employees 920 |
| Stock Exchange NASDAQ | Ticker Symbol UTHR |
Analyst Forecasts
According to 11 analysts, the average rating for UTHR stock is "Buy." The 12-month stock price forecast is 173.11, which is an increase of 5.01% from the latest price.